Loading...
OTCMOPHLY
Market cap4.75bUSD
Dec 24, Last price  
3.41USD
1D
1.79%
1Q
-23.54%
Jan 2017
-52.37%
Name

Ono Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
OTCM:OPHLY chart
P/E
1.97
P/S
0.50
EPS
272.46
Div Yield, %
2,321.46%
Shrs. gr., 5y
-1.36%
Rev. gr., 5y
11.73%
Revenues
502.67b
+12.41%
145,302,000,000148,671,000,000141,711,000,000145,897,000,000136,556,000,000135,986,000,000135,255,000,000145,778,000,000145,393,000,000143,247,000,000135,775,000,000160,284,000,000244,797,000,000261,836,000,000288,634,000,000292,420,000,000309,284,000,000361,361,000,000447,187,000,000502,672,000,000
Net income
127.98b
+13.53%
39,322,000,00036,146,000,00035,271,000,00035,046,000,00023,766,000,00027,878,000,00024,222,000,00024,360,000,00024,120,000,00020,350,000,00012,976,000,00024,979,000,00055,793,000,00050,284,000,00051,539,000,00059,704,000,00075,425,000,00080,519,000,000112,723,000,000127,977,000,000
CFO
110.66b
-30.67%
28,850,000,00039,928,000,00038,678,000,00036,521,000,00024,525,000,00021,301,000,00029,796,000,00021,634,000,00015,661,000,00028,422,000,00031,579,000,00012,842,000,00074,450,000,00015,727,000,00066,774,000,00074,157,000,00073,977,000,00061,829,000,000159,610,000,000110,660,000,000
Dividend
Sep 28, 20230.090515 USD/sh
Earnings
Jan 29, 2025

Profile

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
URL
https://www.ono-pharma.com/
IPO date
Jan 01, 1962
Employees
3,761
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
502,672,000
12.41%
447,187,000
23.75%
361,361,000
16.84%
Cost of revenue
339,570,000
312,729,000
257,943,000
Unusual Expense (Income)
NOPBT
163,102,000
134,458,000
103,418,000
NOPBT Margin
32.45%
30.07%
28.62%
Operating Taxes
35,694,000
30,619,000
24,340,000
Tax Rate
21.88%
22.77%
23.54%
NOPAT
127,408,000
103,839,000
79,078,000
Net income
127,977,000
13.53%
112,723,000
40.00%
80,519,000
6.75%
Dividends
(37,183,000)
(29,742,000)
(27,666,000)
Dividend yield
3.16%
2.20%
1.82%
Proceeds from repurchase of equity
(50,010,000)
(1,000)
(30,007,000)
BB yield
4.24%
0.00%
1.97%
Debt
Debt current
2,310,000
2,490,000
2,301,000
Long-term debt
15,414,000
15,846,000
15,303,000
Deferred revenue
3,350,000
3,322,000
Other long-term liabilities
3,874,000
684,000
771,000
Net debt
(442,792,000)
(470,131,000)
(355,362,000)
Cash flow
Cash from operating activities
110,660,000
159,610,000
61,829,000
CAPEX
(20,829,000)
(14,497,000)
(12,277,000)
Cash from investing activities
48,077,000
(100,259,000)
6,038,000
Cash from financing activities
(89,848,000)
(32,484,000)
(60,237,000)
FCF
23,215,000
147,849,000
31,098,000
Balance
Cash
166,141,000
164,289,000
116,969,000
Long term investments
294,375,000
324,178,000
255,997,000
Excess cash
435,382,400
466,107,650
354,897,950
Stockholders' equity
844,380,000
1,475,061,000
1,323,786,000
Invested Capital
375,958,600
260,332,350
318,145,050
ROIC
40.05%
35.90%
27.16%
ROCE
20.08%
18.48%
15.34%
EV
Common stock shares outstanding
480,039
488,353
496,527
Price
2,454.50
-11.20%
2,764.00
-9.85%
3,066.00
6.09%
Market cap
1,178,255,726
-12.71%
1,349,807,692
-11.33%
1,522,351,782
5.52%
EV
741,107,726
1,575,787,692
1,777,427,782
EBITDA
181,242,000
151,909,000
121,139,000
EV/EBITDA
4.09
10.37
14.67
Interest
229,000
913,000
874,000
Interest/NOPBT
0.14%
0.68%
0.85%